Kidney transplants succeed at high rates in the short term, with about 92% of grafts still working after one year, according to a large systematic review and meta-analysis. That number declines over time: roughly 80% at five years and 68% at ten years. Patient survival follows a similar but slightly more favorable curve, because a person can outlive a failed graft by returning to dialysis or receiving another transplant. Those headline figures, though, obscure enormous variation depending on where the kidney comes from, how well the recipient’s immune system is managed, and a handful of other factors that are worth understanding before or after surgery.
Graft Survival Versus Patient Survival
When transplant professionals talk about “success,” they usually mean two different things, and the distinction matters. Graft survival tracks how long the transplanted kidney keeps functioning. Patient survival tracks how long the recipient stays alive, regardless of what happens to the kidney. A meta-analysis pooling data from dozens of studies worldwide found one-year graft survival of about 92% and patient survival of about 91%. By ten years, graft survival dropped to roughly 68%, while patient survival was closer to 78%.1PubMed Central. Graft and Patient Survival Rates in Kidney Transplantation, and Their Associated Factors: A Systematic Review and Meta-Analysis The gap widens over time because some patients whose grafts fail return to dialysis or get a second transplant. In other words, losing a kidney transplant is not the same as losing your life, though it does mean going back to a much harder form of treatment.
Living Donors Versus Deceased Donors
One of the biggest single predictors of transplant success is whether the kidney comes from a living person or a deceased donor. A large UK cohort study found that receiving a living-donor kidney was associated with about a 6% lower risk of graft failure at five years compared with a deceased-donor kidney, and living-donor recipients gained roughly four extra months of graft life over seven years of follow-up.2PubMed Central. Comparison of outcomes after living and deceased donor kidney transplantation: UK national cohort study That advantage holds even in older recipients. A European registry analysis of elderly patients found that deceased-donor kidneys carried roughly two to three times the hazard of graft failure compared with living-donor kidneys, depending on the type of deceased donation.3PubMed Central. Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort
The reasons are straightforward. A living-donor kidney spends less time without blood flow, is usually healthier to begin with, and can be transplanted on a planned schedule rather than in the middle of the night after a last-minute organ offer. It also allows better immunological matching, since the donor and recipient have time to be tested and prepared.
Not All Deceased-Donor Kidneys Are Equal
Within the deceased-donor category, outcomes vary further depending on how the donor died and the quality of the organ. Kidneys recovered after a donor’s heart stops (donation after circulatory death, or DCD) have historically been viewed with more caution than kidneys from brain-dead donors. A large meta-analysis covering more than 70,000 DCD and 500,000 brain-dead-donor recipients found that DCD kidneys had a modestly higher risk of graft loss at one year, but by ten years the difference had essentially disappeared.4PubMed. Implementation of donation after circulatory death kidney transplantation can safely enlarge the donor pool: A systematic review and meta-analysis DCD kidneys are more prone to delayed function in the early days after surgery, meaning the recipient may need temporary dialysis, but the long-term trajectory catches up. And crucially, receiving a DCD kidney is still far better than staying on dialysis: one study found that DCD transplant recipients had a 56% lower risk of death compared with patients who remained on the waiting list for a standard brain-dead-donor kidney.5PubMed Central. Kidneys from donors after cardiac death provide survival benefit
Kidneys from older or less-than-ideal donors, sometimes called expanded-criteria organs, follow a similar pattern. Their short-term complication rates are higher, but for many patients the alternative is years more on dialysis, which carries its own serious risks. The transplant community has increasingly embraced these organs because a functioning-but-imperfect kidney usually beats no transplant at all.6NefrologÃa. Kidney transplant outcome of expanded criteria donors after circulatory death
Why Transplants Fail
The immune system is the central challenge. Your body recognizes a transplanted organ as foreign and mounts an attack against it. Transplant teams suppress that response with medications, but the immune system sometimes wins anyway. Antibody-mediated rejection has emerged as the leading cause of late graft loss, driven by the recipient’s immune system producing antibodies that target the donor kidney.7PubMed Central. Antibody-mediated rejection: prevention, monitoring and treatment dilemmas Acute episodes of this rejection type occur in roughly 3% to 12% of recipients, most often within the first year. Chronic antibody-mediated rejection, which develops more slowly, has been reported in 8% to 20% of patients over a decade.8PubMed. Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review
There is also cell-mediated rejection, where immune cells directly attack the graft. Treatment outcomes for this form depend heavily on severity. Mild episodes can almost always be reversed with steroids, but the most severe grades leave more than a third of patients without full recovery of kidney function.9PubMed Central. Efficacy of Acute Cellular Rejection Treatment According to Banff Score in Kidney Transplant Recipients: A Systematic Review
Rejection is not the only threat. Recurrence of the original kidney disease, infections, and death with a still-functioning graft are the other major causes of late transplant loss.10PubMed Central. Non-Immunologic Causes of Late Death-Censored Kidney Graft Failure: A Personalized Approach That last category, death with a working graft, often reflects cardiovascular disease or cancer that kills the patient before the kidney fails. In one Brazilian cohort, death with a functioning kidney actually occurred earlier than chronic rejection as a cause of graft loss.11PubMed Central. Long-Term Outcomes among Kidney Transplant Recipients and after Graft Failure: A Single-Center Cohort Study in Brazil BK virus, a common pathogen that most people carry silently, can reactivate under immunosuppression and damage the transplanted kidney. Routine screening has been effective at catching it early and preventing progression to kidney damage.12PubMed Central. BK Virus Nephropathy in Kidney Transplantation: A State-of-the-Art Review
How Much Immunological Matching Matters
The degree to which a donor’s tissue markers match the recipient’s still plays a measurable role, particularly for deceased-donor kidneys. A study of young kidney transplant recipients found that both donor age and the degree of tissue-type mismatch were significantly associated with graft survival for deceased-donor kidneys, while for living-donor kidneys, only mismatch reached significance.13PubMed. Relative importance of HLA mismatch and donor age to graft survival in young kidney transplant recipients In practical terms, a well-matched deceased-donor kidney can approach the outcomes of a living-donor kidney, but a poorly matched one faces steeper odds. Modern allocation systems try to optimize this balance, though a perfect match is rarely possible outside of identical twins.
ABO blood-group incompatibility, once considered an absolute barrier, is now routinely overcome with desensitization protocols that reduce the recipient’s antibodies before surgery. A meta-analysis of ABO-incompatible living-donor transplants found short-term graft survival of about 94% and long-term survival of roughly 89%.14PubMed. Success rate and safety of living donor kidney transplantation in ABO blood group incompatible relatives: A systematic review and meta-analysis Those numbers are slightly lower than ABO-compatible transplants, but the difference is small enough that incompatible transplants are now widely accepted when no compatible donor is available.
How Age and Recipient Health Shape Outcomes
Recipient age has a nuanced relationship with success. Data from the Swiss Transplant Cohort Study showed that each additional year of age at transplant increased the risk of death by about 7%, which is not surprising given that older people are more vulnerable to infections and cardiovascular events. But graft survival followed a U-shaped curve: patients between 35 and 55 had the lowest risk of graft loss, while both younger and older patients faced higher rates.15Transplant International. Age at Time of Kidney Transplantation as a Predictor for Mortality, Graft Loss and Self-Rated Health Status: Results From the Swiss Transplant Cohort Study The higher graft loss in young recipients likely reflects challenges with medication adherence in adolescents and young adults, a well-documented problem.
Among recipients over 70, pre-existing vascular disease is a major concern. A study focused on this age group found that patients with a history of cerebrovascular disease had a 50% rate of graft loss at one year, compared with 6% for those without it. A history of coronary artery disease also predicted worse outcomes at three years.16PubMed Central. Kidney Transplant Outcomes in Recipients Over the Age of 70 Age alone does not disqualify someone from transplant, but cardiovascular health at the time of surgery matters a great deal.
The Medication Adherence Problem
Immunosuppressive drugs are a lifelong commitment after a kidney transplant, and skipping doses is one of the most preventable causes of graft loss. The effect is not always immediate: nonadherence tends to start early but its consequences show up later, as the immune system gradually mounts a response against the unprotected graft.17PubMed Central. Understanding Medication Nonadherence after Kidney Transplant A study using a validated self-report tool found that recipients who reported missing doses had roughly three times the risk of rejection compared with adherent patients.18Nephrology Dialysis Transplantation. Self-reported non-adherence to immunosuppressive medication detected by the BAASIS predicts allograft rejections in kidney transplant recipients
The reasons people skip medication are varied: side effects like weight gain, tremors, and increased infection risk; the sheer monotony of a daily pill regimen for decades; cost and insurance changes; and feeling healthy enough to believe the drugs are unnecessary. The irony is that the better a transplant works, the easier it is to forget why the medications matter.
Lifestyle Factors After Transplant
Immunosuppressive drugs, particularly corticosteroids, can trigger or worsen weight gain, high blood sugar, high blood pressure, and abnormal cholesterol. These metabolic complications are not just inconveniences; they directly threaten the transplanted kidney and the patient’s cardiovascular health. Managing blood glucose, for example, has favorable downstream effects on slowing kidney disease progression.19Transplant International. Dietary Guidelines Post Kidney Transplant: Is This the Missing Link in Recovery and Graft Survival? Regular physical activity helps reduce the risk of post-transplant diabetes, a condition that obesity and immunosuppressive drugs conspire to produce.20PubMed Central. Regular Physical Activity in the Prevention of Post-Transplant Diabetes Mellitus in Patients after Kidney Transplantation Diet modifications and exercise are not just general wellness advice here; they are genuine protective factors for the transplant.
Transplant Versus Staying on Dialysis
For anyone weighing the risks of surgery against the familiarity of dialysis, the survival data are striking. A large study using methods designed to simulate a clinical trial found that transplant recipients gained about two and a half extra years of life over a ten-year follow-up compared with patients who remained on the waiting list receiving dialysis.21JAMA Network Open. Survival Benefit of First Single-Organ Deceased Donor Kidney Transplantation Compared With Long-term Dialysis Across Ages in Transplant-Eligible Patients With Kidney Failure This benefit extends even to people over 70: after an initial high-risk period in the first several months post-surgery, five-year survival was 80% for transplant recipients versus 53% for those remaining on dialysis.22PubMed. Survival after kidney transplantation compared with ongoing dialysis for people over 70 years of age: A matched-pair analysis
Quality of life follows a similar pattern. Systematic reviews consistently find that transplant recipients report substantially better quality of life than patients on dialysis, particularly in areas related to the burden and effects of kidney disease.23PubMed. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes Compared with the general healthy population, transplant recipients tend to report similar quality of life in the first year or two, but physical health ratings can dip somewhat over longer follow-up, likely reflecting the cumulative toll of immunosuppression and chronic disease.24Nephrology Dialysis Transplantation. Mapping health-related quality of life after kidney transplantation by group comparisons: a systematic review
What Happens If a Transplant Fails
About one in five kidney transplant recipients in one historical study maintained graft function for twenty years or more.25PubMed. Twenty-year survivors of kidney transplantation For the rest, graft failure eventually means returning to dialysis and, often, joining the waiting list for another transplant. The good news is that second transplants work. A meta-analysis found that first transplants had modestly better graft survival than second transplants at five years (about 87% versus 78%), but by ten years the gap was no longer statistically significant.26PubMed Central. A meta-analysis of graft survival, patient survival and delayed graft function in first-time and repeat kidney transplants Third transplants, however, showed a more meaningful decline in success rates.
Timing matters. A study of second transplant recipients found that the survival advantage of re-transplantation over staying on dialysis diminished with longer waiting times between the first graft loss and the second surgery. Patients who were re-transplanted within a year of losing their first graft gained about eight months of additional life over ten years of follow-up. Those who waited eight years saw essentially no survival advantage.27PubMed Central. Waiting Time for Second Kidney Transplantation and Mortality The challenge is that re-transplant candidates are often harder to match immunologically because their immune systems have been sensitized by the first graft, which can extend waiting times.
Socioeconomic Disparities in Outcomes
Transplant success is not evenly distributed across the population. Studies in the United States have consistently documented worse outcomes for Black patients, patients with lower incomes, and patients with less education.28PubMed Central. Disparities in kidney transplant outcomes: a review A more recent analysis confirmed that patients living in the most disadvantaged communities had about a 32% higher risk of death after transplant and a higher likelihood of delayed graft function. Patients with public insurance had a 71% higher risk of graft failure compared with those on private insurance.29PubMed. Individual- and Community-Level Socioeconomic Status and Deceased Donor Renal Transplant Outcomes These gaps reflect a tangle of factors: access to follow-up care, ability to afford medications, proximity to transplant centers, underlying health conditions, and structural inequities in the healthcare system. The biology of transplantation is the same for everyone, but the infrastructure around it is not.
New Technologies That Could Change the Numbers
One of the most promising areas of transplant research involves machine perfusion, a technique where donor kidneys are kept alive on a pump with warm, oxygenated blood rather than simply stored on ice. This approach allows clinicians to assess whether a borderline organ is actually viable before committing a patient to surgery. A phase 1 trial of prolonged normothermic perfusion found 100% graft survival at 30 days and comparable kidney function at one year, even though the kidneys had spent nearly twice as long outside the body as conventionally stored organs.30PubMed Central. Prolonged normothermic perfusion of the kidney prior to transplantation: a historically controlled, phase 1 cohort study Researchers have even kept discarded kidneys alive on these machines for up to four days, during which time gene therapies and immune-modifying treatments can be applied directly to the organ.31PubMed. Normothermic machine perfusion applications in kidney transplantation
Two randomized controlled trials have not yet shown a clear clinical benefit of warm perfusion over standard cold storage, so the technique is not a proven game-changer yet. But the logistical advantages are real: longer preservation times give surgical teams more scheduling flexibility and could allow organs to travel farther. A systematic review of both normothermic machine perfusion and a related technique called normothermic regional perfusion found high graft survival rates and reasonable complication profiles for both, with graft utilization rates above 80%.32PubMed. Normothermic Machine Perfusion and Normothermic Regional Perfusion of DCD Kidneys Before Transplantation: A Systematic Review If perfusion technology matures further, it could expand the usable donor pool by rehabilitating kidneys that would currently be discarded, which would matter enormously given that thousands of patients die on waiting lists every year.
What Happens to Living Donors
Because living-donor kidneys produce the best outcomes for recipients, it is worth addressing what happens to the donors themselves. The picture here is more complicated than many prospective donors are told. A large Norwegian study found that kidney donors had a 30% higher risk of death from any cause compared with matched controls who would have been eligible to donate, and a significantly elevated risk of eventually developing kidney failure themselves.33PubMed. Long-term risks for kidney donors However, a well-known U.S. study came to a more reassuring conclusion: donor survival was similar to that of matched controls, and the rate of kidney failure among donors was actually lower than in the general population. About 86% of a subgroup of donors maintained adequate kidney function more than a decade after donation, though roughly a third had developed high blood pressure.34PubMed Central. Long-term consequences of kidney donation
The discrepancy between these studies likely comes down to how the comparison groups were selected. The Norwegian study used population-based controls, while the U.S. study used a control group specifically screened for donation eligibility, which selects for healthier-than-average people. The truth is probably somewhere in between: living donation is safe for most healthy donors, but it does carry a small, real increase in long-term risk that should be discussed openly rather than minimized.